Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2008 1
2010 1
2012 1
2013 2
2016 2
2017 3
2018 4
2019 2
2020 6
2021 10
2022 6
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Griffin MP, et al. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. N Engl J Med. 2020. PMID: 32726528 Clinical Trial.
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Choroidal neovascularization complicating sclerochoroidal calcifications.
Battaglia Parodi M, Arrigo A, Pina A, Calcagno F, Antropoli A, Hassan Farah R, Bandello F, Mansour AM. Battaglia Parodi M, et al. Among authors: calcagno f. Am J Ophthalmol Case Rep. 2021 Nov 26;24:101235. doi: 10.1016/j.ajoc.2021.101235. eCollection 2021 Dec. Am J Ophthalmol Case Rep. 2021. PMID: 34901522 Free PMC article.
[Systemic treatment of locally advanced or metastatic penile cancer].
Gassian N, Frontczak A, El Kaddissi A, Calcagno F, Almotlak H, Barkatz J, Mouillet G, Maurina T, Stein U, Nguyen Tan Hon T, Murez T, Thiery-Vuillemin A. Gassian N, et al. Among authors: calcagno f. Bull Cancer. 2020 Jun;107(5S):S17-S23. doi: 10.1016/S0007-4551(20)30274-5. Bull Cancer. 2020. PMID: 32620202 Review. French.
Safety profile of new anticancer drugs.
Mansi L, Thiery-Vuillemin A, Nguyen T, Bazan F, Calcagno F, Rocquain J, Demarchi M, Villanueva C, Maurina T, Pivot X. Mansi L, et al. Among authors: calcagno f. Expert Opin Drug Saf. 2010 Mar;9(2):301-17. doi: 10.1517/14740330903530663. Expert Opin Drug Saf. 2010. PMID: 20175699 Review.
[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].
de la Fouchardière C, Wassermann J, Calcagno F, Bardet S, Al Ghuzlan A, Borget I, Borson Chazot F, Do Cao C, Buffet C, Zerdoud S, Decaussin-Petrucci M, Godbert Y, Leboulleux S. de la Fouchardière C, et al. Among authors: calcagno f. Bull Cancer. 2021 Nov;108(11):1044-1056. doi: 10.1016/j.bulcan.2021.06.009. Epub 2021 Sep 27. Bull Cancer. 2021. PMID: 34593218 Free article. Review. French.
Indirect Comparison of Lenadogene Nolparvovec Gene Therapy Versus Natural History in Patients with Leber Hereditary Optic Neuropathy Carrying the m.11778G>A MT-ND4 Mutation.
Carelli V, Newman NJ, Yu-Wai-Man P, Biousse V, Moster ML, Subramanian PS, Vignal-Clermont C, Wang AG, Donahue SP, Leroy BP, Sergott RC, Klopstock T, Sadun AA, Rebolleda Fernández G, Chwalisz BK, Banik R, Girmens JF, La Morgia C, DeBusk AA, Jurkute N, Priglinger C, Karanjia R, Josse C, Salzmann J, Montestruc F, Roux M, Taiel M, Sahel JA; the LHON Study Group. Carelli V, et al. Ophthalmol Ther. 2023 Feb;12(1):401-429. doi: 10.1007/s40123-022-00611-x. Epub 2022 Nov 30. Ophthalmol Ther. 2023. PMID: 36449262 Free PMC article.
[Risk factors, prevention and cancers].
Méric JB, Calcagno F, Gary E, Alexandre I. Méric JB, et al. Among authors: calcagno f. Rev Prat. 2013 Jun;63(6):871-7. Rev Prat. 2013. PMID: 23923769 Review. French. No abstract available.
36 results